In its third drug price concessions list for April 2021, the Department of Health and Social Care (DH) has included the following list of medicines.

Drug Pack Size Price Concession
Candesartan 2mg tablets 7 £1.50
Donepezil 10mg orodispersible tablets sugar free 28 £83.89
Eplerenone 50mg tablets 28 £27.71
Esomeprazole 20mg gastro-resistant tablets 28 £4.93
Etoricoxib 120mg tablets 28 £16.51
Etoricoxib 30mg tablets 28 £11.28
Etoricoxib 90mg tablets 28 £12.94
Ivabradine 5mg tablets 56 £5.53
Lamotrigine 200mg tablets 56 £6.06
Nicorandil 10mg tablets 60 £5.40
Nicorandil 20mg tablets 60 £7.99
Pramipexole 88microgram tablets 30 £4.66
Pregabalin 150mg capsules 56 £4.30
Pregabalin 200mg capsules 84 £7.88
Pregabalin 25mg capsules 56 £3.60
Pregabalin 300mg capsules 56 £5.61
Prochlorperazine 5mg tablets 28 £1.60
Repaglinide 1mg tablets 90 £9.79
Repaglinide 2mg tablets 90 £9.09
Tolbutamide 500mg tablets 28 £13.31
Trimethoprim 200mg tablets 6 £1.41
Trimethoprim 200mg tablets 14 £3.29

Second drug price concessions list released on April 27

Drug Pack Size Price Concession
Lamotrigine 25mg tablets 56 £2.77
Letrozole 2.5mg tablets 14 £1.65
Olmesartan medoxomil 20mg tablets 28 £9.50
Olmesartan medoxomil 40mg tablets 28 £14.52
Baclofen 10mg tablets 84 £3.60
Naftidrofuryl 100mg capsules 84 £7.80
Trazodone 100mg capsules 56 £4.05

First drug price concessions list released on April 19

Drug Pack Size Price Concession
Chlorpromazine 50mg tablets 28 £16.50
Eplerenone 25mg tablets 28 £12.00
Etoricoxib 60mg tablets 28 £16.24
Lamotrigine 100mg tablets 56 £5.14
Lamotrigine 50mg tablets 56 £4.50
Olmesartan medoxomil 10mg tablets 28 £8.85
Pregabalin 100mg capsules 84 £6.99
Pregabalin 50mg capsules 84 £6.28
Pregabalin 75mg capsules 56 £5.22
Sulfasalazine 500mg gastro-resistant tablets 112 £21.20
Sulfasalazine 500mg tablets 112 £18.80
Trimethoprim 50mg/5ml oral suspension sugar free 100 £12.50
Zonisamide 100mg capsules 56 £52.49

 

If you want to share your stories and/or experiences with us, please send an email to [email protected]

LEAVE A REPLY